China Universal Asset Management Co. Ltd. Grows Stock Holdings in uniQure (NASDAQ:QURE)

China Universal Asset Management Co. Ltd. lifted its position in uniQure (NASDAQ:QURE) by 57.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,093 shares of the biotechnology company’s stock after buying an additional 3,663 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in uniQure were worth $50,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC increased its stake in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. Total Clarity Wealth Management Inc. acquired a new stake in uniQure during the 2nd quarter worth approximately $74,000. SG Americas Securities LLC purchased a new position in uniQure in the 2nd quarter valued at approximately $79,000. Cubist Systematic Strategies LLC grew its stake in shares of uniQure by 130.9% in the second quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 14,454 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new stake in shares of uniQure during the third quarter worth $116,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $5.72 on Friday. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The firm has a market capitalization of $278.55 million, a P/E ratio of -0.96 and a beta of 0.95. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. The company’s fifty day moving average price is $5.70 and its 200 day moving average price is $5.74.

uniQure (NASDAQ:QURE) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.08. The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $3.47 million. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. As a group, sell-side analysts predict that uniQure will post -4.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the subject of a number of recent research reports. Raymond James reiterated an “outperform” rating and issued a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. The Goldman Sachs Group boosted their price objective on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Friday, September 20th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Thursday, October 17th. Finally, HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, uniQure presently has a consensus rating of “Hold” and a consensus price target of $19.50.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.